Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy
(replacement of antibodies, which are infection-fighting proteins) in patients with a type of
blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy)
and have an abnormal immune system putting them at increased risk of infection.